Ningbo Menovo Pharmaceutical Co., Ltd.

Equities

603538

CNE100002Y25

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 23/05/2024 BST 5-day change 1st Jan Change
12.84 CNY -0.47% Intraday chart for Ningbo Menovo Pharmaceutical Co., Ltd. -5.93% -32.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Approves Menovo Pharma's Type 2 Diabetes Drug MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Menovo Pharmaceutical Unit Gets Approval to Register Vildagliptin Tablets MT
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on July 20, 2023 CI
Menovo Pharma's Unit Gets Nod to Market Clopidogrel Hydrogen Sulfate Tablets MT
Menovo Pharma Gets Nod to Market Raw Drug Ingredient for Hypertension Into EU Market; Shares Up 3% MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) dropped from S&P Global BMI Index CI
Ningbo Menovo Pharma Registers Seizure Drug in China MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Menovo Pharmaceutical Unit's Rosuvastatin Calcium Passes Drug Regulator's Technical Review MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) added to S&P Global BMI Index CI
Ningbo Menovo Pharma Registers Blood Pressure Drug MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 652 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 651.999948 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors. CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive funding from Ningbo Menovo Holding Group Co., Ltd. CI
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on August 15, 2022 CI
Menovo Pharmaceutical's Unit Gets Nod to Own Olmesartan Medoxomil Tablets MT
Menovo Pharma Gets European Certification for Diet Drug MT
Menovo Pharma Gets Registration Certificate for Moxifloxacin Hydrochloride Tablets MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Menovo Pharma Unit's Diet Control Drug Passes Regulator Evaluation MT
Menovo Pharma's API Obtains European Certificate MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chart Ningbo Menovo Pharmaceutical Co., Ltd.
More charts
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations. The Company is mainly engaged in three businesses. The contract development and manufacturing organization (CDMO) business mainly provides pharmaceutical companies with CDMO services for the entire preparation industry chain. The specialty API business is mainly engaged in the production and sales of APIs. The preparation business is mainly engaged in the production and sales of preparations. The Company's main products include valsartan, losartan, perindopril, rosuvastatin calcium, atorvastatin calcium and pregabalin. The Company's products are mainly used in cardiovascular, central nervous, antiviral, hypoglycemic, gastrointestinal and other therapeutic areas. The Company mainly conducts its businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.84
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603538 Stock
  4. News Ningbo Menovo Pharmaceutical Co., Ltd.
  5. Menovo Pharma Unit's Diet Control Drug Passes Regulator Evaluation